Background

Harmonising assessment of men with prostate cancer (PCA) is key for both clinical research and practice.

- Core outcome sets (COS) are an agreed minimum set of outcomes.
- As part of the PIONEER Consortium, we aim to develop COS to cover the various stages and treatments for prostate cancer (Figure 1).

Introduction

This systematic review aims to determine if there is a need for a non-metastatic castration resistant prostate cancer (nmCRPC) COS (Figure 1: Research overview to develop PIONEER COS).

Methods


- The search criteria were extended to include metastatic castration resistant prostate cancer (mCRPC), hormone resistant prostate cancer (HRPC), metastatic prostate cancer (mPC).

Results and Discussion

- Literature searches identified 1,262 citations for men with nmCRPC, mCRPC, HRPC, mPC from which five RCTs met the inclusion criteria.

Figure 1: Research overview to develop PIONEER COS

Figure 2: PRISMA diagram

- reports outcomes for nmCRPC, which differ from the already identified outcomes in the PIONEER metastatic outcome set.

Figure 3: Outcomes identified in nmCRPC systematic review (not captured in mPCa COS)

Harmonising assessment of men with prostate cancer (PCA) is key for both clinical research and practice.

• Core outcome sets (COS) are an agreed minimum set of outcomes.
• As part of the PIONEER Consortium, we aim to develop COS to cover the various stages and treatments for prostate cancer (Figure 1).

Figure 1: Research overview to develop PIONEER COS

Identification

- 34 Citations identified through PubMed (nmCRPC)
- 210 Citations identified through PubMed (mPC)
- 1018 Citations identified from EAU Guidelines
- 6 RCTs identified which meet inclusion criteria
- 5 RCTs identified which meet inclusion criteria
- 1262 Citations included from abstract screening
- 51 Full text screenings
- 3 SRs identified which meet inclusion criteria
- No new outcomes were identified for nmCRPC compared with the metastatic setting.

Conclusion

- Very few new outcomes were identified for nmCRPC as compared with the metastatic setting.
- Therefore, PIONEER currently does not recommend a specific COS for nmCRPC.
- If in future treatments options warrant new RCTs and different outcome measurements, this recommendation may change.